Prognostic factors associated with major cytogenetic response and with survival in chronic phase ± clonal evolution (N = 365)
| Parameter . | n . | Major cytogenetic response, n (%) . | P . | Survival at 2 y, % . | P . |
|---|---|---|---|---|---|
| Age | |||||
| Younger than 60 y | 243 | 163 (67) | .04 | 90 | .6 |
| 60 y or older | 122 | 68 (56) | 89 | ||
| Splenomegaly, cm bcm | |||||
| None | 291 | 203 (70) | < .0001 | 94 | .0006 |
| 1-9 | 29 | 12 (41) | 74 | ||
| 10 or greater | 43 | 15 (35) | 62 | ||
| Hemoglobin | |||||
| Less than 10 g/dL | 39 | 15 (38) | .001 | 75 | .0004 |
| 10 g/dL or more | 326 | 216 (66) | 92 | ||
| Platelets | |||||
| 450 × 109/L or less | 284 | 194 (68) | .0003 | 91 | .2 |
| More than 450 × 109/L | 81 | 37 (46) | 85 | ||
| Peripheral blasts | |||||
| None | 271 | 198 (73) | < .0001 | 96 | < .0001 |
| Any percentage | 94 | 33 (35) | 72 | ||
| Marrow blasts | |||||
| Less than 5% | 312 | 220 (71) | < .0001 | 95 | < .0001 |
| 5% or more | 53 | 11 (21) | 61 | ||
| Peripheral basophils | |||||
| Less than 7% | 318 | 214 (67) | < .0001 | 91 | .2 |
| 7% or more | 47 | 17 (36) | 81 | ||
| Marrow basophils | |||||
| Less than 5% | 304 | 207 (68) | < .0001 | 92 | .05 |
| 5% or more | 61 | 24 (39) | 78 | ||
| WBCs | |||||
| Less than 10 × 109/L | 177 | 134 (76) | 94 | ||
| 10-49 × 109/L | 131 | 72 (55) | < .0001 | 85 | .2 |
| 50 × 109/L or more | 57 | 25 (44) | 87 | ||
| Sokal risk group | |||||
| Good | 73 | 60 (82) | 97 | ||
| Intermediate | 70 | 42 (60) | .01 | 94 | .2 |
| Poor | 21 | 15 (71) | 81 | ||
| Cytogenetic clonal evolution | |||||
| No | 295 | 193 (65) | .1 | 92 | .002 |
| Yes | 70 | 38 (54) | 77 | ||
| CML duration | |||||
| Shorter than 12 mo | 53 | 43 (81) | 96 | ||
| 12-35 mo | 136 | 91 (67) | .001 | 93 | .02 |
| 36 mo or longer | 176 | 97 (55) | 85 | ||
| Ph+ at start of therapy | |||||
| Less than 90% | 91 | 83 (91) | < .0001 | 96 | .08 |
| 90% or more | 269 | 146 (54) | 89 | ||
| Disease group prior to IFN treatment | |||||
| Hematologic resistant | 30 | 10 (33) | 84 | ||
| Hematologic refractory | 22 | 9 (41) | 81 | ||
| CG resistant | 94 | 59 (63) | < .0001 | 93 | .06 |
| CG refractory | 61 | 53 (87) | 96 | ||
| IFN-α intolerant | 131 | 83 (63) | 89 |
| Parameter . | n . | Major cytogenetic response, n (%) . | P . | Survival at 2 y, % . | P . |
|---|---|---|---|---|---|
| Age | |||||
| Younger than 60 y | 243 | 163 (67) | .04 | 90 | .6 |
| 60 y or older | 122 | 68 (56) | 89 | ||
| Splenomegaly, cm bcm | |||||
| None | 291 | 203 (70) | < .0001 | 94 | .0006 |
| 1-9 | 29 | 12 (41) | 74 | ||
| 10 or greater | 43 | 15 (35) | 62 | ||
| Hemoglobin | |||||
| Less than 10 g/dL | 39 | 15 (38) | .001 | 75 | .0004 |
| 10 g/dL or more | 326 | 216 (66) | 92 | ||
| Platelets | |||||
| 450 × 109/L or less | 284 | 194 (68) | .0003 | 91 | .2 |
| More than 450 × 109/L | 81 | 37 (46) | 85 | ||
| Peripheral blasts | |||||
| None | 271 | 198 (73) | < .0001 | 96 | < .0001 |
| Any percentage | 94 | 33 (35) | 72 | ||
| Marrow blasts | |||||
| Less than 5% | 312 | 220 (71) | < .0001 | 95 | < .0001 |
| 5% or more | 53 | 11 (21) | 61 | ||
| Peripheral basophils | |||||
| Less than 7% | 318 | 214 (67) | < .0001 | 91 | .2 |
| 7% or more | 47 | 17 (36) | 81 | ||
| Marrow basophils | |||||
| Less than 5% | 304 | 207 (68) | < .0001 | 92 | .05 |
| 5% or more | 61 | 24 (39) | 78 | ||
| WBCs | |||||
| Less than 10 × 109/L | 177 | 134 (76) | 94 | ||
| 10-49 × 109/L | 131 | 72 (55) | < .0001 | 85 | .2 |
| 50 × 109/L or more | 57 | 25 (44) | 87 | ||
| Sokal risk group | |||||
| Good | 73 | 60 (82) | 97 | ||
| Intermediate | 70 | 42 (60) | .01 | 94 | .2 |
| Poor | 21 | 15 (71) | 81 | ||
| Cytogenetic clonal evolution | |||||
| No | 295 | 193 (65) | .1 | 92 | .002 |
| Yes | 70 | 38 (54) | 77 | ||
| CML duration | |||||
| Shorter than 12 mo | 53 | 43 (81) | 96 | ||
| 12-35 mo | 136 | 91 (67) | .001 | 93 | .02 |
| 36 mo or longer | 176 | 97 (55) | 85 | ||
| Ph+ at start of therapy | |||||
| Less than 90% | 91 | 83 (91) | < .0001 | 96 | .08 |
| 90% or more | 269 | 146 (54) | 89 | ||
| Disease group prior to IFN treatment | |||||
| Hematologic resistant | 30 | 10 (33) | 84 | ||
| Hematologic refractory | 22 | 9 (41) | 81 | ||
| CG resistant | 94 | 59 (63) | < .0001 | 93 | .06 |
| CG refractory | 61 | 53 (87) | 96 | ||
| IFN-α intolerant | 131 | 83 (63) | 89 |
bcm indicates below coastal margin.